Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:18 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 9,539 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed No phase listed Observational Results available

Compression Nail for Tibiocalcaneal Arthrodesis

NCT03780452
View directory record Official record
Conditions
Subtalar Arthritis, Ankle Arthritis
Interventions
novel dynamic compression intramedullary nail
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 110 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 3, 2026, 5:18 PM EST
Completed Not applicable Interventional Results available

A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

NCT01572948
View directory record Official record
Conditions
COPD
Interventions
roflumilast, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 4 Interventional Results available

TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up

NCT00336284
View directory record Official record
Conditions
Patient Indicated for an ICD
Interventions
Home Monitoring, In-Office Conventional Follow-up
Other
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Nov 3, 2026, 5:18 PM EST
Recruiting Phase 3 Interventional

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352
View directory record Official record
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
80,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

NCT02431247
View directory record Official record
Conditions
Immunodeficiency Virus Type 1, Human
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 3 Interventional

Obese Patients With Type 2 Diabetes

NCT00029848
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Non-Insulin-Dependent, Obesity in Diabetes
Interventions
Rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Nov 3, 2026, 5:18 PM EST
Recruiting No phase listed Observational

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

NCT02674100
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Registry
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Nov 3, 2026, 5:18 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Ketone Supplementation in Adolescents Post-Concussion

NCT04079907
View directory record Official record
Conditions
Concussion, Mild, Concussion, Severe, Concussion, Brain, Concussive Injury, Sport Injury, Sports Injuries in Children
Interventions
Ketone, Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
13 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Nov 3, 2026, 5:18 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
View directory record Official record
Conditions
HIV Infections
Interventions
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
Biological · Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

NCT00001136
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 5:18 PM EST
Withdrawn Not applicable Interventional

Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery

NCT01043211
View directory record Official record
Conditions
Back Pain
Interventions
Lidocaine Hydrochoride Injection, without epinephrine, Normal Saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 4 Interventional Results available

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

NCT00377234
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Risedronate, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Nov 3, 2026, 5:18 PM EST
Terminated Phase 2 Interventional

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

NCT05655299
View directory record Official record
Conditions
Psoriasis
Interventions
VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 1 Interventional

An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates

NCT00818584
View directory record Official record
Conditions
Candida
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
48 Hours to 120 Days
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Nov 3, 2026, 5:18 PM EST
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

NCT00001038
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 2 Interventional Results available

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

NCT01853748
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Paclitaxel, Trastuzumab emtansine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 3, 2026, 5:18 PM EST
Terminated Phase 2 Interventional Results available

Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism

NCT01439867
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Interventions
Cinacalcet hydrochloride, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days to 2189 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 1 Interventional

Pharmacokinetic Evaluation of Testosterone Gel (1%)

NCT00193700
View directory record Official record
Conditions
Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions
Testosterone Gel (1%)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
13 Years to 17 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Birmingham, Alabama • Torrance, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2006 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

NCT03861936
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
OnabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 3 Interventional Results available

Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

NCT00784134
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
Alteplase, Normal saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Nov 3, 2026, 5:18 PM EST
Terminated Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

NCT00113399
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, docetaxel, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
125
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Nov 3, 2026, 5:18 PM EST
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 3, 2026, 5:18 PM EST
Completed Phase 3 Interventional Results available

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00110019
View directory record Official record
Conditions
Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
218
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Nov 3, 2026, 5:18 PM EST